公开(公告)号：US11986630B2

公开(公告)日：2024-05-21

申请号：US16788892

申请日：2020-02-12

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Ashutosh Zade ,  Jason O'Connor ,  Trang Ly ,  Yibin Zheng ,  Connor Gullifer ,  Kyle Grover

IPC: A61M5/172 ,  G16H20/17

CPC classification number: A61M5/1723 ,  G16H20/17 ,  A61M2202/07 ,  A61M2205/18 ,  A61M2205/3569 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/581 ,  A61M2205/583 ,  A61M2230/201

Abstract: The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.

公开(公告)号：US11833329B2

公开(公告)日：2023-12-05

申请号：US17123369

申请日：2020-12-16

Applicant: INSULET CORPORATION

Inventor： Joon Bok Lee ,  Jason O'Connor ,  Yibin Zheng

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2005/14208 ,  A61M2205/3303 ,  A61M2205/3569 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2230/201

Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide techniques to implement functionality to receive blood glucose measurements over a period of time. An average of missing blood glucose measurement values may be maintained over a predetermined time period. A count of a number of missing blood glucose measurement values over a period of time may be established. A controller may calculate a divergence of the number of missing blood glucose measurement values over the period of time from the average of missing blood glucose measurements over the predetermined time period. Based on a value of the divergence, a determination that a safety constraint for delivery of insulin is to be reduced. The safety constraint may be reduced by a predetermined percentage. An instruction to deliver an insulin dosage may be generated according to the reduced safety constraint may be forwarded to a wearable drug delivery device.

公开(公告)号：US11565039B2

公开(公告)日：2023-01-31

申请号：US16599729

申请日：2019-10-11

Applicant: INSULET CORPORATION

Inventor： Jason O'Connor ,  Joon Bok Lee ,  Ian McLaughlin ,  John D'Arco

IPC: A61M5/158 ,  A61M5/142 ,  A61M31/00 ,  A61B5/145 ,  A61B5/00

Abstract: A drug delivery device may include an Inertial Measurement Unit (IMU) is provided. The IMU may include an accelerometer, a magnetometer, or a gyroscope. Motion parameters may be detected when the drug delivery device is shipped, being prepared for activation for use, or during use. The IMU may provide data indicative of a rapid deceleration, such as when a package containing the drug delivery device is dropped, or some other physical event experienced by the drug delivery device. The drug delivery device may also include internal or external pressure sensors or a blood glucose sensor that may coordinate with the IMU to provide additional feedback regarding the status of the device or user. A controller of the drug delivery device may generate a response depending on the particular parameters being monitored or may change device operational parameters as a result of detected system events.

公开(公告)号：US11241532B2

公开(公告)日：2022-02-08

申请号：US16116071

申请日：2018-08-29

Applicant: Insulet Corporation

Inventor： David Nazzaro ,  John D'Arco ,  Jason O'Connor ,  Ian McLaughlin

IPC: A61M5/168 ,  A61B5/145 ,  A61M5/142 ,  A61M5/172 ,  A61B5/00

Abstract: A drug delivery system having a drug delivery device and an associated sensor is provided. The sensor can be associated with a sensing site on user. The drug delivery device can be positioned over the sensor in any rotational position and can be associated with an infusion site on the user. The close positioning of the sensor and the drug delivery device allows data from the sensor to be relayed to the drug delivery device and then on to a remote control device. Further, the drug delivery device can be replaced at the end of its duration of use, which is shorter than the duration of use of the sensor, without disturbing the sensor. Subsequent drug delivery devices can then be used with the sensor while allowing each corresponding infusion site to be changed, thereby providing more efficient operation of the drug delivery system.

公开(公告)号：US11090434B2

公开(公告)日：2021-08-17

申请号：US17079393

申请日：2020-10-23

Applicant: Insulet Corporation

Inventor： Jason O'Connor ,  Daniel Allis ,  David Nazzaro ,  John R. Bussiere ,  John D'Arco

IPC: A61M5/172 ,  G16H40/63 ,  G16H20/17 ,  A61M5/142

Abstract: Systems and methods for automatically delivering medication to a user. An automated drug delivery system may include a sensor and a wearable automated drug delivery device. The wearable automated drug delivery device may be configured to couple to the skin of a user and may include a controller and a pump. The pump may be configured to output the medication. The controller may be within the wearable automated drug delivery device. The sensor may be coupled to the user and may be configured to collect information regarding the user. The controller of the wearable automated drug delivery device may use the collected information to locally determine an amount of medication to be output from the wearable automated drug delivery device and cause delivery of the amount of medication.

公开(公告)号：US12226612B2

公开(公告)日：2025-02-18

申请号：US17715589

申请日：2022-04-07

Applicant: INSULET CORPORATION

Inventor： Yibin Zheng ,  Joon Bok Lee ,  Ashutosh Zade ,  Jason O'Connor

IPC: A61M5/172 ,  G06F17/17

Abstract: Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.

公开(公告)号：US12121700B2

公开(公告)日：2024-10-22

申请号：US17377801

申请日：2021-07-16

Applicant: Insulet Corporation

Inventor： James Graham ,  Joon Bok Lee ,  Jason O'Connor

IPC: A61M5/00 ,  A61M5/172 ,  G16H10/60 ,  G16H20/17 ,  G16H40/67 ,  A61B5/00 ,  A61B5/145 ,  A61B5/1495 ,  A61M5/142 ,  A61M5/168 ,  G16H20/00 ,  G16H20/10

CPC classification number: A61M5/1723 ,  G16H10/60 ,  G16H20/17 ,  G16H40/67 ,  A61B5/00 ,  A61B5/0002 ,  A61B5/14532 ,  A61B5/1495 ,  A61B5/4836 ,  A61B5/4839 ,  A61B5/4848 ,  A61B5/7225 ,  A61B5/725 ,  A61B5/7275 ,  A61M5/142 ,  A61M5/14244 ,  A61M5/14248 ,  A61M5/14276 ,  A61M5/168 ,  A61M5/16877 ,  A61M2205/00 ,  A61M2205/18 ,  A61M2205/3561 ,  A61M2205/3584 ,  A61M2205/3592 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/505 ,  A61M2205/52 ,  A61M2205/581 ,  A61M2205/582 ,  A61M2205/583 ,  A61M2205/8206 ,  A61M2230/00 ,  A61M2230/20 ,  A61M2230/201 ,  A61M2230/63 ,  G16H20/00 ,  G16H20/10

Abstract: Disclosed are techniques and a device operable to determine a total amount of insulin delivered to the user over a predetermined time period. The total amount of insulin includes a total basal dosage delivered in basal dosages and a total bolus dosage delivered in bolus dosages over the predetermined time period. A proportion of the total amount of insulin delivered to the user provided via the total basal dosage amount over the predetermined time period is calculated. In response determining the proportion of the total amount of insulin attributed to the total basal dosage amount of insulin exceeds a threshold, an average basal dosage to be delivered within a subsequent time period that is approximately equal to the threshold may be determined. An instruction may be generated and output to deliver a modified basal dosage that substantially maintains the average basal dosage over the subsequent time period.

公开(公告)号：US11911596B2

公开(公告)日：2024-02-27

申请号：US18186539

申请日：2023-03-20

Applicant: INSULET CORPORATION

Inventor： Joon Bok Lee ,  Mengdi Li ,  Jason O'Connor ,  Yibin Zheng

IPC: G08B1/08 ,  A61M5/172 ,  G16H10/40 ,  G16H10/60 ,  G16H20/17 ,  G16H40/60 ,  G16H40/67 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70 ,  H04L67/141

CPC classification number: A61M5/1723 ,  G16H10/40 ,  G16H10/60 ,  G16H20/17 ,  G16H40/60 ,  G16H40/67 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70 ,  A61M2202/07 ,  A61M2205/3584 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2230/20 ,  A61M2230/201 ,  H04L67/141

Abstract: Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.

公开(公告)号：US11904140B2

公开(公告)日：2024-02-20

申请号：US17330115

申请日：2021-05-25

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Yibin Zheng ,  Jason O'Connor ,  Trang Ly

IPC: A61M5/172 ,  G16H20/17 ,  A61B5/145 ,  A61B5/00 ,  A61M5/142 ,  G06Q30/0283

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  A61B5/4839 ,  A61M5/142 ,  G06Q30/0283 ,  G16H20/17 ,  A61M2005/14208 ,  A61M2205/52 ,  A61M2230/201

Abstract: The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage).

公开(公告)号：US11684713B2

公开(公告)日：2023-06-27

申请号：US16796853

申请日：2020-02-20

Applicant: Insulet Corporation

Inventor： Steven Diianni ,  Ian McLaughlin ,  Jason O'Connor ,  Robert Campbell ,  Kevin Schmid

IPC: A61M5/145 ,  A61B5/145 ,  A61B5/1486 ,  A61M5/142 ,  F04B9/02 ,  A61M5/172 ,  A61M5/158 ,  A61M5/32 ,  A61M5/14

CPC classification number: A61M5/14566 ,  A61B5/14532 ,  A61B5/14865 ,  A61M5/1452 ,  A61M5/14244 ,  A61M5/14248 ,  A61M5/158 ,  A61M5/1723 ,  F04B9/02 ,  A61M5/3291 ,  A61M2005/1403 ,  A61M2005/14252 ,  A61M2005/14506 ,  A61M2230/201 ,  F04C2270/041

Abstract: Disclosed is a fluid delivery device including a fluid reservoir and a transcutaneous access tool fluidly coupled to the fluid reservoir, wherein the transcutaneous access tool includes a needle or a trocar. The fluid delivery device may further include a transcutaneous access tool insertion mechanism for deploying the transcutaneous access tool, wherein the insertion mechanism is configured to insert and retract the needle/trocar in a single, uninterrupted motion.